-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Downgrades Calumet to Sell, Lowers Price Target to $15

Benzinga·02/04/2025 10:36:17
Listen to the news
UBS analyst Manav Gupta downgrades Calumet (NASDAQ:CLMT) from Neutral to Sell and lowers the price target from $20.5 to $15.